CMS certification 053304
Children's Hospital of Orange County
1201 W La Veta Ave, Orange, CA 92868
This page brings together federal quality data for this hospital: its CMS star rating, patient survey results, emergency department times, and death, complication, infection and readmission rates, each compared with the national rate. Everything here comes from CMS and NPPES, the federal sources themselves - not from us.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: Oct 2024 – Sep 2025.
Not reported for this hospital
CMS had too few cases here to publish results for deaths, complications, infections caught in the hospital, readmissions and return visits. That is common at small, rural and specialty hospitals, and says nothing either way about quality.
Clinicians registered at this address
390 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 59 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Pediatrics | 74 |
| Clinical | 45 |
| Neonatal-Perinatal Medicine | 25 |
| Psychologist | 23 |
| Social Worker | 15 |
| Clinical Child & Adolescent | 13 |
| Pharmacist | 12 |
| Neurology with Special Qualifications in Child Neurology | 10 |
| Dietitian, Registered | 8 |
| Pediatric Critical Care Medicine | 8 |
| Pediatric Hematology-Oncology | 8 |
| Physician Assistant | 8 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $1.6M
- 2020 $1.8M
- 2021 $1.6M
- 2022 $2M
- 2023 $2.3M
- 2024 $1.8M
- 2025 $2.4M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Space rental and facility fees | $123,400 | 16 |
| Education | $71,328 | 2 |
| Grants | $40,500 | 3 |
| Medical devices and supplies on long-term loan | $14,481 | 62 |
| Speaking, teaching and other services | $8,300 | 7 |
| Debt forgiveness | $4,330 | 4 |
| Charitable contributions | $3,029 | 1 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Pfizer INC. | $819,242 | 18 |
| Ultragenyx Pharmaceutical Inc. | $307,363 | 20 |
| Vertex Pharmaceuticals Incorporated | $128,252 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $107,024 | 7 |
| Jazz Pharmaceuticals INC. | $105,476 | 10 |
| Masimo Corporation | $94,638 | 70 |
| Smith+Nephew, Inc. | $87,795 | 2 |
| Biogen, Inc. | $57,501 | 1 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| DETERMINATION OF THE UTILITY OF PFIZERS PNEUMOCOCCAL URINE ANTIGEN TEST IN CHILDREN 3 MONTHS 90 DAYS TO 5 YEARS 72 MONTHS OF AGE WITH COMMUNITY AC… PFIZER INC. | $663,778 |
| DTX401-CL301 Ultragenyx Pharmaceutical Inc. | $250,406 |
| ETIOLOGY OF EMPYEMA IN CHILDREN YOUNGER THAN 18 YEARS OLD IN ORANGE COUNTY CALIFORNIA A ROLE FOR MOLECULAR DIAGNOSISWI246357 PFIZER INC. | $114,074 |
| Evaluation of clinical outcomes following COBLATION Intracapsular Tonsillectomy (CIT): a retrospective, singlearm, multi-center consecutive case seri… Smith+Nephew, Inc. | $87,795 |
| Children's Hospital of Orange County/ Data Collection for Pediatric Noninvasive Total Hemoglobin Spot-Check Monitoring Masimo Corporation | $80,285 |
| A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX-121/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fib… VERTEX PHARMACEUTICALS INCORPORATED | $79,332 |
| ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-C… JAZZ PHARMACEUTICALS INC. | $69,026 |
| An Open Label, Single Cohort Study to Assess the Pharmacokinetic Profile of Nusinersen (BIIB058) Administered Via the ThecaFlex DRx System (PIERRE-PK) Biogen, Inc. | $57,501 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about Children's Hospital of Orange County
Does Children's Hospital of Orange County have an emergency room?
No. CMS does not list emergency services at Children's Hospital of Orange County.
Does Children's Hospital of Orange County receive money from drug and device companies?
Drug and device makers reported $2.4M in payments to Children's Hospital of Orange County for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.